GH Guardant Health (GH) Q2 FY26 earnings call
Guardant Health delivered a landmark quarter with broad-based revenue growth driven by strong performance in Oncology, Biopharma & Data, and Screening segments. Key milestones included FDA approvals for Guardant360 Liquid CDx and a lower-COGS Shield workflow, alongside significant Shield adoption catalysts like ACS guideline inclusion and UnitedHealth Group coverage, positioning the company for accelerated future growth while managing increased investments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
GH operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Oncology test volumes | ~86KOncology test volumes rose 47% to approximately 86,000 tests, up from 59,000 in the prior year period.Source: earnings call transcript | ~104KOncology test volumes rose 63% to approximately 104,000 tests, up from 64,000 in the prior year period with strength across all products.Source: earnings call transcript | — |
| Shield tests Screening | ~44KWe delivered $42 million of Shield testing revenue driven by approximately 44,000 tests compared to $6 million revenue and approximately 9,000 tests in Q1 of 2025.Source: earnings call transcript | ~66KWe delivered $53 million of Shield testing revenue, driven by approximately 66,000 tests compared to $15 million of revenue and approximately 16,000 tests in Q2 of 2025.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.